{"schema_version":"secwatch.filing_event.v1","accession":"0001701541-24-000040","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.269920+00:00","generated_at":"2026-05-30T05:24:41.492659+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Black Diamond Therapeutics reports Q3 net loss of $15.6M; BDTX-1535 Phase 2 data","bullets":["Net loss of $15.6M in Q3 2024 vs $23.0M in Q3 2023; cash and investments $112.7M, sufficient into Q2 2026.","R&D expenses decreased to $12.9M from $16.2M YoY due to workforce efficiencies and reduced early discovery.","Announced restructuring in Oct 2024 to prioritize BDTX-1535 and extend cash runway; deprioritized BDTX-4933.","Initial Phase 2 data for BDTX-1535 in EGFRm NSCLC: 42% ORR in 19 patients with osimertinib resistance mutations; DOR ~8+ months in first 3 PRs.","Expects to disclose initial Phase 2 data in first-line and updated recurrent setting data plus FDA feedback in Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001701541-24-000040","json":"https://secwatch.observer/filing/0001701541-24-000040.json","markdown":"https://secwatch.observer/filing/0001701541-24-000040.md","text":"https://secwatch.observer/filing/0001701541-24-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000170154124000040/0001701541-24-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000170154124000040/bdtx-20241105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:24:41.492659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}